As per the agreement Servier will engage BioInvent to screen its proprietary n-CoDeR library for antibodies specific to the undisclosed target.
Servier will also have access to BioInvent’s in-house pre-clinical capacities in selecting an antibody candidate for development.
BioInvent will receive a licensing fee, research support and potential milestone payments of more than EUR11m, as well as royalty on future sales of the product.
Servier R&D president Emmanuel Canet said they will reinforce capacity of using biologics to address cancer targets and look forward to benefit from Bioinvent’s experience in the field.